Purkiss Capital Advisors’s AbbVie ABBV Stock Holding History

Purkiss Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	4,355 +260	+6%	+$55.9K	0.42%	56
2026 Q1	$891K	Buy	4,095 +6	+0.1%	+$1.33K	0.39%	65
2025 Q4	$934K	Sell	4,089 -7	-0.2%	-$1.59K	0.44%	49
2025 Q3	$948K	Buy	4,096 +651	+19%	+$133K	0.45%	52
2025 Q2	$639K	Buy	3,445 +166	+5%	+$30.9K	0.36%	63
2025 Q1	$687K	Buy	3,279 +1	+0%	+$194	0.52%	40
2024 Q4	$582K	Buy	+3,278	New	+$603K	0.5%	42

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Purkiss Capital Advisors's ABBV Position: Q2 2026 in Review

Purkiss Capital Advisors increased its AbbVie (ABBV) stake by 6.3% in Q2 2026, buying an estimated $55.9K and bringing the position to 4,355 shares worth $1.1M. The position accounts for 0.42% of the portfolio, ranked #56.

Purkiss Capital Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 1,993 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Purkiss Capital Advisors held 4,355 shares of AbbVie worth $1.1M as of Q2 2026.
Purkiss Capital Advisors bought 260 AbbVie shares in Q2 2026, an estimated $55.9K.
AbbVie made up 0.42% of Purkiss Capital Advisors's portfolio in Q2 2026, its #56 holding.
Purkiss Capital Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
1,993 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Purkiss Capital Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.